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INTRODUCTION
The notion that 3D-conformal high dose (>75 Gy) radia-
tion produces superior outcome to low dose radiation (<70
Gy) during prostate cancer radiotherapy has been revealed
by several studies, in which the dose-response has been ob-
served for a dose range of 63-81 Gy (1-3). More recently ultra-
high dose intensity-modulated radiotherapy (IMRT) with
dose escalation of even up to 86.4 Gy has been reported for
localized prostate cancer (4). However, an important obstacle
to high-dose high-precision radiotherapy for localized pro-
state cancer is that the target position changes depending on
the state of the rectum and bladder. Many methods have been
used in an attempt to minimize the inaccuracy that results
from the positional shift of the prostate during prostate can-
cer radiotherapy. Such procedures include the daily localiza-
tion method that uses a fiducial marker (5, 6) or B-mode ac-
quisition and targeting (BAT) (Nomos Corporation, Sewick-
ly, PA, U.S.A.) (7), and the rectal balloon (8-11) that immo-
bilizes the prostate itself. Growing interest in the use of a
rectal balloon for immobilizing the prostate led to our devel-
opment of a unique rectal balloon that has been applied dur-
ing prostate cancer radiotherapy in our institution since 2003.
The rectal balloon technique has two major advantages: it
immobilizes the prostate and reduces treatment-related tox-
icity by saving the rectal wall (12-14). The rectal balloon res-
tricts prostate motion by reducing both the inter- and intra-
fractional movements. This minimizes the error caused by
the motion of the prostate making it unnecessary to change
the isocenter. The subsequent relative reduction in the rectal
irradiation volume is expected to significantly reduce early
and chronic side effects. To achieve both benefits effectively,
reproducibility of the position and shape of the rectal balloon
is required. Several studies have reported that the rectal bal-
loon can reproduce the intra-pelvic position and reduce the
planning target volume (PTV) margin (11, 12, 15, 16). How-
ever, other studies have reported that the movement of the
anterior surface of the balloon remained high (17, 18). Sev-
eral factors affect the intra-pelvic positioning of a rectal bal-
loon including the air volume inside the balloon, the shape
(symmetry) of the balloon, the insertion depth of the rectal
tube, and bowel gas. To date, the effects of these factors have
not been studied in depth.
Here, we have developed a unique rectal balloon that dilates
symmetrically allowing high reproducibility in shape, has a
scale that indicates the depth of insertion, and immobilizes
not only the prostate but also the seminal vesicles due to the
positioning of the tip of the rectal tube inside the balloon.
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Positional Reproducibility and Effects of a Rectal Balloon in Prostate
Cancer Radiotherapy
Despite the increasing use of the rectal balloon in prostate cancer radiotherapy,
many issues still remain to be verified objectively including its positional reproducibili-
ty and relevance to treatment morbidity. We have developed a custom rectal balloon
that has a scale indicating the depth of insertion and dilates symmetrically ensur-
ing positional reproducibility. Fifty patients with prostate cancer treated by definitive
3D-conformal radiotherapy (3D-CRT) or intensity-modulated radiotherapy (IMRT)
with rectal balloon were analyzed. Each of first five patients undergone computed
tomography (CT) three times with a rectal balloon. The positional reproducibility was
tested by Intraclass Correlation Coefficient (ICC) from the CT-to-CT fusion images.
Planning variables and clinical acute toxicities were compared between when or
not applying balloon. An ICC of greater than 0.9 in all directions revealed an excel-
lent reproducibility of the balloon. Rectal balloon improved considerably the mean
dose and V45Gy-V65Gy in plan comparison, and especially in 3D-CRT the rectal volume
exposed to more than 60 Gy dropped from 41.3% to 19.5%. Clinically, the balloon
lowered acute toxicity, which was lowest when both the balloon and IMRT were ap-
plied simultaneously. The rectal balloon carries excellent reproducibility and reduces
acute toxicity in 3D-CRT and IMRT for prostate cancer.
Key Words : Rectal Balloon; Prostatic Neoplasms; Radiotherapy, Intensity-Modulated; 3D Conformal Radio-
therapy; Acute Toxicity
Received : 8 June 2008
Accepted : 22 October 2008Rectal Balloon in Prostate Radiotherapy 895
There have been several reports on the positional reproducibil-
ity of rectal balloons but few have demonstrated positional
reproducibility using a systematic and objective method. To
our knowledge, the present study is the first to demonstrate
the positional reproducibility of rectal balloons using system-
atic methods and reasonable statistical analysis. The position-
al reproducibility was tested by Intraclass Correlation Coef-
ficient (ICC) from the computed tomography (CT)-to-CT
fusion images. A comparative planning study verified the
dosimetrical benefits of the rectal balloon by comparing the
dose distribution between the cases with and without insert-
ing the rectal balloon. And also we examined patient toler-
ance and toxicity of the rectal balloon in 50 patients treated
using the balloon.
MATERIALS AND METHODS
Development of a highly reproducible rectal balloon
During the development of a rectal balloon, the position-
al and formative reproducibility, control of insertion depth,
length of immobilization, and optimal volume of the rectal
balloon have to be considered. For positional reproducibili-
ty, we used a balloon that allowed symmetric dilatation so
that the rectal balloon could maintain high formative repro-
ducibility during each treatment while still being pressured
evenly by its surrounding structures. In addition, a scale was
placed on the rectal tube to indicate the depth of insertion.
The tip of the rectal tube was placed inside the balloon so that
the balloon immobilized not only the upper part of the pros-
tate but also the level of the seminal vesicles (Fig. 1, 2A). The
basic form of the rectal balloon was a rectal tube used for ene-
mas, with a plastic support inside the rectal tube for easy ad-
vancement once the tube was inserted. In addition, a 60 mL
syringe was used to inflate the balloon and forceps were used
to prevent air leaking. Before the balloon was inserted, it was
capped with a latex condom and lubricating jelly was applied.
In order to measure the depth of insertion of the balloon, grad-
uations were marked on the rectal tube. To assess air leakage,
we left a balloon inflated with 60 mL of air for seven days and
confirmed that no air leaked from the balloon during that time.
The rectal balloon was applied to patients as follows. First,
a deflated rectal catheter was inserted gently into the patient
with his knees bent. Then, the balloon was inflated slowly
with 60 mL of air. Forceps were used to prevent air leakage.
The graduations on the rectal balloon were recorded so that
each insertion would be made at the same depth. Finally, the
patient straightened his legs and radiotherapy was conduct-
ed in the supine posture.
Positional reproducibility of the rectal balloon
To prove the positional reproducibility of the rectal bal-
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Fig. 1. The rectal balloon and its application to the patient. (A) Constituents of the rectal balloon. (B) Measurement of the insertion depth
of the rectal balloon using a marked scale on the rectal tube (black arrow). (C) Pre-treatment supine position. (D) Inflated rectal balloon.896 J.H. Cho, C.-G. Lee, D.R. Kang, et al.
loon, CT scans were performed 3 times in each of the first 5
patients with the rectal balloon. A total of 15 CT image sets
were registered on the Philips treatment planning platform
using the Pinnacle software and went through CT-to-CT
fusion, in which the landmark was the pelvic bone. On each
CT image set, the upper, middle, and lower sections passing
through the prostate were selected. And the rectangles pass-
ing the edge of the rectal balloon on a total of 45 cross-sec-
tional images were drawn on the radiotherapy planning sys-
tem (RTPS). Then, we could get a coordinate value, which
makes the variation of the x-axis and z-axis of the balloon
edge measurable objectively from each line at 4 directions
of the rectangles from the RTPS (Fig. 2). Through this pro-
cedure, 180 coordinates were obtained from 15 CT image
sets. We defined 1 class as 15 coordinates from a level of the
prostate and each direction of the rectangles, resulting in 12
classes. To determine that the coordinates representing the
position of the rectal balloon reproduce with statistical sig-
nificance for the classes, ICC was obtained (19, 20). We cal-
culated how many patients we needed for statistically mean-
ingful data of the reproducibility of CT taken 3 consecutive
times from the same patient using the Power Analysis and
Sample Size (PASS) program. The results showed that the
number of patients suggested by the PASS program should
be 5 or more at the 5% level of significance, a power of 80%,
baseline ICC r0=0.50, and expected ICC r1=0.90 or higher.
During actual treatment, the position of the rectal balloon
was monitored weekly by port film or electronic-portal imag-
ing device (Fig. 3).
Radiation treatment
For the bladder, CT-simulation or treatment was performed
in the supine posture after the bladder was filled for a specif-
ic period of time within a comfortable range for the patient.
Elective pelvic lymph node irradiation was performed only
when the possibility of pelvic lymph node metastasis esti-
Fig. 2. Positional reproducibility test for the rectal balloon. (A) Three levels of balloon displacement measurements on the fused sagittal
image between the first (gray) and second CT (thermal). (B) Displacement measurement of the mid-rectangles between the first, second,
and third CT. (C, D) Displacement of the balloon on the third CT compared to the first CT. (E, F) Displacement of the balloon on the first
CT compared to the second CT. (G, H) Displacement of the balloon on the first CT compared to the third CT.
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Fig. 3. Identification of the rectal balloon (blackarrow) on: (A) the
verification film (RIT 113
�) and (B) the EPID image on a lateral beam
port. d1 represents the sagittal diameter of the balloon, d2 repre-
sents the distance between the anterior surface of the balloon and
the top of the couch table.
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mated by the Roach score was greater than 30%.
3D-CRT was planned using the ADAC Pinnacle3
� system,
and the fraction dose was 1.8 Gy. Pelvic lymph nodes and
distal seminal vesicles were excluded through the first cone
down (CD) at 45.0-50.4 Gy, and proximal seminal vesicle and
periprostatic fat were excluded through the second CD at
59.4 Gy. The prostate gland and gross tumor volume (GTV)
were irradiated up to 70.2 Gy. IMRT was applied using the
simultaneous integrated boost (SIB) technique, in which the
target volumes of three layers (high-dose PTV (HPTV), mid-
dose PTV (MPTV) and low-dose PTV (LPTV) were conto-
ured resulting in a different fractional dose for each target.
HPTV included the prostate gland and any extraprostatic
gross tumor, MPTV included the periprostatic fat tissue and
proximal seminal vesicles, and LPTV included the distal semi-
nal vesicles, set-up errors and pelvic lymph nodes. Irradiation
was performed with a total of 28 fractions. The HPTV received
a total dose of 70 Gy at 2.5 Gy per fraction, the MPTV received
a total dose of 60.2 Gy at 2.15 Gy per fraction, and the LPTV
received a total dose of 50.4 Gy at 1.8 Gy per fraction. In pa-
tients with a Roach score of 30 or less, the pelvic lymph node
chain was excluded from the LPTV. IMRT plans were calcu-
lated using the Corvus inverse planning system (Nomos Cor-
poration), and step and shoot IMRT was carried out using
PRIMUS
� (Siemens Medical Solution, Erlangen, Germany).
For patients treated by 3D-CRT in this study, the rectal
balloon was not applied to the first treatment but cone down
because it was thought that 39 fractions could be a burden
to both radiotherapy technicians and patients of the use of
rectal balloons. Nowadays, since the procedure takes just 1
or 2 min with the proper training, most 3D-CRT patients
feel comfortable with the insertion of rectal balloons from the
first treatment. In IMRT patients in this study, we applied
the rectal balloon from the beginning since the period of treat-
ment was reduced by more than 2 weeks with the hypofrac-
tionated regimen. Posterior shielding or rectal block was not
performed throughout the treatment.
Comparative planning study between cases treated with
and without the rectal balloon
We chose 10 patients in whom both CT images with and
without insertion of the balloon were available and conduct-
ed 3D-CRT and IMRT for each patient and compared the
distribution of rectal doses between the cases. Target volumes
were prostate only in 5 patients and whole pelvis in the oth-
ers. Dose statistics such as mean rectal dose, V45Gy-V65Gy (VnGy,
volume receiving n Gy) and dose volume histogram (DVH)
were compared between plans from each treatment method
with or without the rectal balloon. For the 3D-CRT plan with
the rectal balloon, we assumed that the balloon was applied
from the beginning according to the current treatment sc-
heme. Non-parametric Wilcoxon rank sum test was perform-
ed to prove statistical significance between the plans with and
without the balloons in each treatment. In addition, the 3D-
CRT plan with the balloon was compared to the IMRT plan
with no balloon.
Evaluation of acute toxicity and patient tolerance
Fifty prostate cancer patients who had received radical ra-
diotherapy (3D-CRT 35, IMRT 15 patients) between Febru-
ary 2004 and June 2006 were evaluated for acute toxicity and
patient tolerance. Table 1 shows the details of the patients and
their treatment. Examination was made once a week during
the period of treatment, once a month for three months after
treatment, once every three months for a year after treatment,
and afterward once every six months. Toxicity related to treat-
ment was assessed at each visit and acute toxicity was mea-
sured using the Radiation Therapy Oncology Group (RTOG)
toxicity score (21). Acute toxicity was defined as the side
effects related to radiotherapy that occurred during treatment
and within three months after the completion of treatment.
RESULTS
Excellent positional reproducibility of the rectal balloon
Excellent positional reproducibility of the rectal balloon
was proved objectively from ICC’s greater than 0.90 in all
PSA, prostate-specific antigen; 3D-CRT, three-dimensional conformal
radiotherapy; IMRT, intensity-modulated radiotherapy.
Characteristics Number Percentage
Clinical T stage
T1 7 14
T2 19 38
T3 22 44
T4 2 4
Clinical N stage
N0 46 92
N1 4 8
PSA
≤10 14 28
>10 ≤20 12 24
>20 24 48
Gleason score
2-6 21 42
7-10 29 58
Pre-treatment hormone
No 28 56
Yes 22 44
Radiotherapy technique
3D-CRT 35 70
IMRT 15 30
Target volume
Prostate only 24 48
Whole pelvis 26 52
Table 1. Patient characteristics898 J.H. Cho, C.-G. Lee, D.R. Kang, et al.
directions. The anterior line of the balloon, which represents
the interface between the rectum and prostate, showed an
ICC of 0.94 and above in all of the upper, middle, and lower
levels, giving us high reliability for prostate immobilization
(Table 2). The standard deviation (SD) of the positional dis-
placement ranged from 1.3 mm to 2.8 mm, demonstrating
an accuracy of less than 3 mm (Table 2, 3). Among them,
every directions of the low rectangle had a SD larger than 2
mm, which might be attributed to the small balloon volume
in the lower part of the rectum closer to the anal sphincter.
Interestingly, the SD of the anterior line, where the prostate
meets the anterior rectal wall, was smaller than that of the
posterior line in both the upper and middle rectangles. The
excellent reproducibility was mainly due to the creative char-
acteristics of our rectal balloon, including the symmetry of
rectal balloon dilatation, a scale indicating the depth of inser-
tion, and the ability of the balloon to immobilize the semi-
nal vesicle as well as the prostate due to the positioning of
the tip of the rectal tube inside the balloon.
Rectal balloon technique dosimetry: superiority of the
rectal balloon in terms of rectal wall saving
The rectal balloon improved rectal wall saving compared
CT, computed tomography; ICC, intraclass correlation coefficient; 95%
CI, 95% confidence interval.
Level of Direction of
rectan- coordinate ICC (95% CI) F (P value)
gles classes
Upper Anterior 0.939 (0.760, 0.993) 46.911 (<0.001)
Posterior 0.903 (0.646, 0.988) 28.950 (<0.001)
Right 0.937 (0.753, 0.993) 45.281 (<0.001)
Left 0.974 (0.888, 0.997) 111.222 (<0.001)
Middle Anterior 0.969 (0.871, 0.996) 94.589 (<0.001)
Posterior 0.929 (0.726, 0.992) 40.000 (<0.001)
Right 0.929 (0.727, 0.992) 40.107 (<0.001)
Left 0.961 (0.841, 0.996) 75.310 (<0.001)
Low Anterior 0.949 (0.795, 0.994) 56.565 (<0.001)
Posterior 0.911 (0.669, 0.989) 31.577 (<0.001)
Right 0.910 (0.668, 0.989) 31.425 (<0.001)
Left 0.916 (0.687, 0.990) 33.907 (<0.001)
Table 2. Intraclass correlation coefficient for positional repro-
ducibility of rectal balloon
Direction Anterior Posterior Rt. lateral Lt. lateral
Level (cm) (cm) (cm) (cm)
Upper 0.13 0.25 0.13 0.13
Middle 0.18 0.24 0.17 0.16
Lower 0.26 0.28 0.22 0.24
Table 3. Standard deviations of each direction of rectal balloon
*Comparison between no balloon and balloon of 3D-CRT/IMRT with Wilcoxon rank sum test; 
� Comparison between no balloon of IMRT and balloon of  3D-
CRT with Wilcoxon rank sum test.
The rectal percent volumes receiving 65 Gy, 60 Gy, 50 Gy, and 45 Gy are presented as V65Gy, V60Gy, V50Gy, and V45Gy, respectively.
3D-CRT, three-dimensional conformal radiotherapy; IMRT, intensity-modulated radiotherapy; IQR, InterQuartile Range; Dmean, mean dose.
3D-CRT IMRT
P value
� Dose No Balloon Balloon
P value*
median (IQR) median (IQR)
No Balloon Balloon
P value*
median (IQR) median (IQR)
Dmean (Gy) 51.73 (3.76) 41.98 (3.46) 0.001 41.12 (3.49) 33.77 (4.73) 0.003 0.734
V65Gy (%) 29.68 (11.41) 14.89 (3.05) 0.001 7.42 (2.29) 8.85 (3.74) 0.623 0.017
V60Gy (%) 41.33 (12.56) 19.53 (8.01) 0.001 13.59 (4.12) 12.67 (5.08) 0.385 0.017
V50Gy (%) 59.63 (9.50) 36.13 (15.81) 0.001 27.5 (7.13) 19.13 (4.08) 0.009 0.273
V45Gy (%) 68.95 (14.39) 44.05 (20.17) 0.001 37.03 (9.89) 24.53 (2.23) 0.005 0.678
Table 4. Rectal dose statistics according to radiotherapy technique and use of balloon
Fig. 4. Change in dose distribution and dose volume histogram
(DVH) according to the balloon in prostate cancer radiotherapy.
(A) 3D-CRT without balloon. (B) 3D-CRT with balloon. (C) IMRT
without balloon. (D) IMRT with balloon. (E) Rectal DVH.
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to patients who did not receive rectal balloon treatment (Table
4, Fig. 4). In detail the benefit of rectal wall sparing using
the rectal balloon was more remarkable in patients receiv-
ing 3D-CRT than IMRT.
In the 3D-CRT plan, use of the rectal balloon resulted in
a dose-reduction effect of more than 15 Gy in the mean rec-
tal dose and decreased significantly all the values of V65Gy,
V60Gy, V50Gy and V45Gy up to 15-20%. In the IMRT plan, the
mean rectal dose was reduced from 41.1 Gy to 33.8 Gy th-
rough the use of the rectal balloon but in IMRT, it did not
exceed 15% regardless of whether the balloon was used or
not. In some of the high-dose ranges greater than 65 Gy, the
rectal volume increased slightly during IMRT when the bal-
loon was used, probably due to the effects of the balloon push-
ing against the rectal wall. However, this increase was so small
that it was not clinically relevant. V50Gy and V45Gy in IMRT
decreased significantly with the balloon.
When we compared the plans between no balloon IMRT
and balloon 3D-CRT, there were no significant differences in
the mean rectal dose, V50Gy and V45Gy, implying that use of
rectal balloon in 3D-CRT could produce favorable dosime-
try effect comparable to that of IMRT without balloon.
Acute toxicity and patient tolerance in the definitive
radiotherapy using rectal balloon for prostate cancer
Since many of the patients in this study had an initial pr-
ostate-specific antigen (PSA) of over 20 and an advanced pr-
ostate cancer of over T3 and GS7, in many cases the target
volume included the pelvic lymph nodes. Inclusion of the
pelvic lymph nodes within the target volume is an impor-
tant variable not only in the plan comparison but also with
respect to the gastrointestinal (GI) complication rate. Thus,
we examined the occurrence of acute complications in the
patients with respect to the radiotherapy technique applied
and the target volume (Table 5). In addition, when determin-
ing whether to use the rectal balloon, we compared our results
with recent reports (8, 10, 22-27) describing the complica-
tions that result from 3D-CRT and IMRT (Table 6). Based
on these previous studies, fewer rectal complications were
observed when a rectal balloon was used and IMRT was ap-
plied. In this study, we also found that in patients receiving
prostate only IMRT, Grade I complications were detected in
17% (1/6) of patients whereas Grade II complications were
not observed. In cases of whole pelvis IMRT, the percentage
of Grade I complications increased to 33%, but again Grade
II complications were relatively rare. In patients receiving
RTOG, Radiation Therapy Oncology Group; 3D-CRT, three-dimensional conformal radiotherapy; IMRT, intensity-modulated radiotherapy; GI, gastrointesti-
nal; GU, genitourinary.
GI complication (%) GU complication (%) Target Total No. of
volume patients G 0 G I G II G III/IV G 0 G I G II G III/IV
3D-CRT Prostate only 18 56 33 11 0 22 44 33 0
Whole pelvis 17 29 47 24 0 18 47 35 0
IMRT Prostate only 6 83 17 0 0 17 67 17 0
Whole pelvis 9 56 33 11 0 22 56 22 0
Table 5. Analysis of acute complications according to target volume and technique (RTOG Grade)
3D-CRT, three-dimensional conformal radiotherapy; IMRT, intensity-modulated radiotherapy; GI, gastrointestinal; GU, genitourinary; Gy, gray; T.D., total
prescribed dose; F.S., fraction size; Dmean, mean dose; Ref, reference; N/A, not available.
Prescription (Gy) Rectal
balloon Technique
use
Rectal
Dmean
(Gy)
Ref
T.D. F.S.
1. Kupelian et al. No IMRT 70 2.5 N/A 30 55 15 0 0 15 62 22 1 0 (23)
3D-CRT 78 2.0 N/A 12 70 18 0 0 19 63 17 1 0
2. Zelefsky et al. No IMRT 81-86.4 1.8 N/A 74 22 4 0 0 33 38 28 0 0 (24)
3. Pollack et al. No IMRT 76 2.0 N/A 52 40 8 0 0 N/A N/A N/A N/A N/A (25)
3D-CRT 78 2.0 N/A 17 14 67 0 0 6 58 24 3 0
4. De Meerleer et al. No IMRT 74-78 2.0 54.8 34 39 27 0 0 10 47 36 7 0 (27)
5. Bastasch et al. Yes IMRT 77 2.2 N/A 68 14 18 0 0 N/A N/A N/A N/A N/A (8)
6. Teh et al. Yes IMRT 70 2.0 35.0 83 11 6 0 0 27 38 35 0 0 (10)
7. Goldner et al. Yes 3D-CRT 70-74 2.0 N/A 52 31 17 0.5 0 N/A N/A N/A N/A N/A (22)
8. Current study Yes IMRT 70 2.5 34.3 67 27 7 0 0 20 60 20 0 0
3D-CRT 70.2 1.8 43.5 43 40 17 0 0 20 46 34 0 0
Table 6. Acute complications following 3D-CRT & IMRT for prostate cancers in patients with and without balloon
GI complication (%)
G 0 G I G II GIII GIV
GU complication (%)
G 0 G I G II GIII GIV
Radiotherapy
Authors900 J.H. Cho, C.-G. Lee, D.R. Kang, et al.
3D-CRT with the rectal balloon, side effects were rarely ob-
served when radiotherapy was applied to the prostate only.
However, when the pelvic lymph nodes were included in
3D-CRT, the reduction of side effects by the rectal balloon
was insignificant.
None of the patients who had started treatment with the
rectal balloon stopped treatment due to toxicity-related com-
plications. During the period of study, one patient refused the
insertion of the balloon from the beginning because existing
hemorrhoids were too painful. Three patients that had start-
ed radiotherapy, later complained of pain during insertion
of the rectal balloon due to worsening hemorrhoids, but all
of them finished the treatment with the rectal balloon using
oral analgesics. Most of the patients without hemorrhoids
reported that the rectal balloon was tolerable throughout the
entire period of treatment. The volume of air in the balloon
was set at 60 mL for all of the patients. 
DISCUSSION
The use of the rectal balloon during prostate cancer radio-
therapy is increasing, but many issues still remain to be ver-
ified objectively including the positional reproducibility, opti-
mal shape and volume, insertion depth control and relevance
to clinical data. We have developed a uniquely designed rec-
tal balloon that could achieve high reproducibility, immo-
bilization effects not only for the prostate but also for the level
of the seminal vesicles, and controls the insertion depth of
the rectal tube. This study demonstrated the positional repro-
ducibility of this rectal balloon using systematic methods and
reasonable statistical analysis. We then verified the benefit
of using the rectal balloon with respect to dosimetrical and
clinical aspects through a comparative planning study and
analysis of acute toxicities in patients treated with 3D-CRT
and IMRT using the rectal balloon. Thus, the results and fig-
ures from this study provide meaningful information concern-
ing the clinical use of the rectal balloon.
Many factors influence the intra-pelvic positioning of a rec-
tal balloon including the air volume inside the balloon, the
shape (symmetry) of the rectal balloon, the insertion depth
of the rectal tube, and bowel gas. Of these factors, only the
adequate air volume of the rectal balloon has been studied
previously. The volume of a rectal balloon varies between 40-
120 mL (8, 11-13, 15-18, 22, 28-30). Hille et al. (30) have
reported that 60 mL allows increased reproducibility com-
pared with 40 mL. With respect to rectal wall saving, it is
considered desirable to inflate the balloon as much as is tol-
erable to the patient. Our institution applied 60 mL uniform-
ly to all patients.
Another factor affecting the positioning of a rectal balloon
is the shape of the balloon. Some reports have provided pho-
tographs of the rectal balloons actually used during therapy
(11-13, 17, 22). Based on these reports, we have divided the
shape of the rectal balloons into three subtypes according to
the symmetry of balloon expansion and the exposure of the
rectal tube tips. These groups include symmetric ballooning
and the rectal tube tip remaining inside the balloon (11);
symmetric ballooning and the rectal tube tip exposed at the
top of the balloon (12, 13, 22); and asymmetric dilatation
(17). In our case, the rectal tube tip was inside the balloon and
the balloon expanded symmetrically, similar to that described
by Watcher et al. (11). While exposure of the rectal tube tip
at the top of the rectal balloon restricts cranial distension, the
tip inside the balloon is advantageous in that the balloon can
immobilize not only the prostate but also the seminal vesi-
cles. In addition, symmetric dilatation provided by our bal-
loon seems better for minimizing the effect of torsion when
inserting the rectal tube and for distributing pressure evenly
throughout the pelvis. One study describing the large move-
ment of the anterior surface of the rectal balloon uses an asym-
metric-shaped rectal balloon, which may account for the sig-
nificant amount of movement (17).
The insertion depth of the rectal tube should be consistent.
Generally, the tube is inserted fully before the balloon is inflat-
ed, and then the tube is removed until the dilated balloon is
gently lodged on the anal sphincter. However, the position
may differ depending on the patient’s tension. El-Bassiouni
et al. (18) reported that the craniocaudal directional varia-
tion was as large as 6.4 mm (±2.5 mm SD). However, this
may be controlled to some degree by scaling the rectal tube
(Fig. 1B). Scaling itself is very easily applicable to any rectal
Fig. 5. Balloon displacement by rectal gas identified on the mega-
voltage CT (MVCT) scan of helical tomotherapy. (A) Rectal gas
and balloon on MVCT image (yellow). (B) Balloon on the initial CT
image (gray). (C) Unmatched balloon surface between the MVCT
and initial CT image.
A B
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balloon.
The last important factor affecting the positioning of rec-
tal balloons is rectal gas. Although it does not happen fre-
quently, rectal gas can change the position of the rectal wall
and the prostate by pushing the rectal balloon. In the daily
megavoltage CT (MVCT) of helical tomotherapy introduced
recently to our institution, we observed that rectal gas causes
a relatively large deviation in the positioning of rectal bal-
loons (Fig. 5). Since the gas does not disappear immediately,
in cases where the deviation is large, we would recommend
deferring the treatment for several hours or until the follow-
ing day. As there are various factors that affect the intra-pelvic
positional variation of rectal balloons, it is considered mean-
ingful to combine image-guided radiotherapy (IGRT) such
as BAT and MVCT with rectal balloon treatment.
The rectal balloon technique not only immobilized the
prostate, but also reduced treatment-related toxicity through
relative rectal wall saving. The relative reduction of rectal
irradiation volume is expected to reduce early and chronic side
effects significantly. In general, side effects from radiotherapy
depend on the dose applied to specific organs and the volume
percentage. In cases like hollow viscus that has radial disten-
sibility, irradiation of the whole circumference would lead to
stricture and an increased likelihood of bleeding when sub-
stances pass through. However, if only a small part of hollow
viscus receives high-dose irradiation, then the remainder ma-
intains radial distensibility. Subsequently, pressure from pass-
ing substances will be low, and obstruction and bleeding will
be less likely. The rectal balloon has a tendency to push the
anterior rectal wall toward the prostate. However, since the
rectum and the prostate almost touch each other in most cases,
an overlapping margin for the PTV is inevitable. In contrast,
the expansion of the whole rectal wall by the balloon reduces
the volume of the rectum exposed to high-dose radiation,
which in turn reduces the side effects. The build-up effect ca-
used by air inside the balloon may also contribute partially
to decreased side effects (31).
Besides irradiation volume, acute side effects from prostate
cancer radiotherapy can be affected by various factors (27)
including planning variables (i.e., whether to include margin,
seminal vesicles, pelvic lymph nodes), differences in toxicity
scoring scales, and auto-medication as an over-the-counter
drug. Accordingly, these factors need to be considered togeth-
er when analyzing acute side effects. In our research, a relative-
ly large number of patients had locally advanced prostate can-
cers, so pelvic lymph nodes were included in the target vol-
ume in many patients. Furthermore, during 3D-CRT, the
rectal balloon was applied from 45-50 Gy considering the
long treatment period of conventional fractionation. There-
fore, we assessed patient tolerance and acute toxicity depend-
ing on the technique and target volume. We found that pa-
tients were able to tolerate the rectal balloon technique very
well. Side effects were least when the rectal balloon was used
in IMRT, although they were also quite rare when 3D-CRT
was applied to the prostate only.
Recently, hypofractionated radiotherapy is widely perform-
ed due to a low α /βratio in prostate cancers (32-35). The st-
udy sample used here also included patients treated by hypo-
fractionated IMRT schedule delivering 70 Gy at 2.5 Gy/frac-
tion in 5.5 weeks. In these cases, the reduction in the treat-
ment period makes it easier to use rectal balloons. Consider-
ing the low α /βratio in prostate cancers, hypofractionation
is expected to increase the tumor control probability consid-
erably. However, the increasing effect on geometric uncer-
tainties can reduce tumor control probability (36). Thus, the
benefit of hypofractionation can be maximized through min-
imizing geometric uncertainties using the rectal balloon. In
addition, the shortening of treatment period would be expect-
ed to increase the practicality of using this technique.
In conclusion, the present study demonstrates the position-
al reproducibility of rectal balloons using systematic methods
and reasonable statistical techniques. In addition, we showed
that the rectal balloon reduces acute side effects consistently
with the result of a dosimetrically outstanding plan.
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